153039-16-8

Basic information

• Product Name: 1-Pyrrolidinecarboxylicacid,3,3-diMethyl-2-oxo-,1,1-diMethylethylester
• Synonyms: 1-Pyrrolidinecarboxylicacid,3,3-diMethyl-2-oxo-,1,1-diMethylethylester;tert-butyl 3,3-dimethyl-2-oxopyrrolidine-1-carboxylate;Tert-Butyl 3,3-Dimethyl-2-Oxopyrrolidine-1-Carboxylate(WXC04334)
• CAS NO: 153039-16-8
• Molecular Formula: C11H19NO3
• Molecular Weight: 213.27346
• EINECS: -0
• Mol File: 153039-16-8.mol

Chemical Properties

• Boiling Point: 311.2±11.0 °C(Predicted)
• Appearance: /
• Density: 1.056±0.06 g/cm3(Predicted)
• PKA: -2.12±0.40(Predicted)
• CAS DataBase Reference: 1-Pyrrolidinecarboxylicacid,3,3-diMethyl-2-oxo-,1,1-diMethylethylester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylicacid,3,3-diMethyl-2-oxo-,1,1-diMethylethylester(153039-16-8)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylicacid,3,3-diMethyl-2-oxo-,1,1-diMethylethylester(153039-16-8)

Safety Data

• Hazardous Substances Data: 153039-16-8(Hazardous Substances Data)

Usage

Class

The chemical belongs to the class of organic compounds known as pyrrolidine carboxylic acids.

Type

It is an ester derivative of pyrrolidine carboxylic acid.

Uses

The chemical is commonly used in organic synthesis and pharmaceutical research due to its potential biological activity.

Role

It also has a role as an intermediate in the production of other chemicals.

Potential

It may have uses in the development of new drugs and therapeutic agents.

Upstream product

• 4831-43-0 3,3-dimethylpyrrolidin-2-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 85909-08-6 tert-butyl 2-oxopyrrolidine-1-carboxylate 
• 74-88-4 methyl iodide 
• 171017-18-8 tert-butyl 3-methyl-2-oxo-1-pyrrolidine-carboxylate 

Downstream Products

• 153039-17-9 2,2-dimethyl-4-[[(2-methylpropan-2-yl)oxyoxomethyl]amino]butanoic acid 
• 4831-43-0 3,3-dimethylpyrrolidin-2-one 
• 1246609-91-5 ethyl 6-(4-(tert-butoxycarbonylamino)-2-methylbutan-2-yl)-2-(phenylamino)nicotinate 

Relevant articles and documents

Structural studies of {6Li} 2-lithiopyrrolidines using NMR spectroscopy

A selection of N-substituted 2-lithiopyrrolidines were prepared and their structures were investigated by 6Li and 13C NMR spectroscopy. Evidence is presented for aggregation and dynamic solvation effects, depending on the nature of the N-substituent and substituents on the pyrrolidine ring. Studies were performed with N-Boc (coordinating carbonyl group), N-methoxyethyl (coordinating methoxy group) and N-alkyl (no coordinating group) heterocycles to represent three different classes of organolithiums: dipole-stabilized, unstabilized and chelated, and unstabilized.

N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF

An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.

4-AMINO OR 4-ALKOXY-SUBSTITUTED ARYL SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS

Disclosed are compounds of Formula (I), Formula (II), or a salt thereof: Formula (I) Formula (II) which compounds have properties for inhibiting Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (I), Formula (II) or their salts, and methods of treating pain disorders, cough, and itch using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

2-(1-HETEROARYLPIPERAZIN-4-YL)METHYL-1,4-BENZODIOXANE DERIVATIVES AS ALPHA2C ANTAGONISTS

Compounds of formula I (formula I), wherein A is an optionally substituted five-membered unsaturated heterocyclic ring containing 1, 2 or 3 N, O or S ring heteroatom(s) exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases or conditions of the peripheric or central nervous system.

ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF

The invention relates to nicotinamide derivatives which can be used as anticancer drugs.

EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE

Masked nitrogen-substituted and oxygen-substituted neopentyl sulfonyl ester prodrugs of acamprosate, pharmaceutical compositions comprising such prodrugs, and methods of using such prodrugs and compositions thereof for treating diseases are disclosed. In particular, acamprosate prodrugs exhibiting enhanced oral bioavailability and methods of using acamprosate prodrugs to treat neurodegenerative disorders, psychotic disorders, mood disorders, anxiety disorders, somatoform disorders, movement disorders, substance abuse disorders, binge eating disorder, cortical spreading depression related disorders, tinnitus, sleeping disorders, multiple sclerosis, and pain are disclosed.

PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES

A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, formula (I): wherein: R1 is C3-8-cycloalkyl; X is O, NR7 or C3-6-heterocycloalkyl; R2 is aryl, heteroaryl, fused or unfused aryl-C3-6-heterocycloalkyl or fused or unfused heteroaryl-C3-6-heterocycIoalkyl, each of which is optionally substituted by one or more substitutents selected from aryl, heteroaryl, C1-6-alkyl, C3-7-cycloalkyl and a group A, wherein said C1-6-alkyl group is optionally substituted by one or more substituents selected from aryl, heteroaryl, R10 and a group A, said heteroaryl group is optionally substituted by one or more R10 groups; and wherein said C3-6-heterocycloalkyl group optionally contains one or more groups selected from oxygen, sulfur, nitrogen and CO; R3 is C1-6-alkyl optionally substituted by one or more substituents selected from aryl, heteroaryl, -NR4R5, -OR6, -NR7(CO)R6, -NR7(CO)NR4R5, -NR7SO2R6, -NR7COOR7, -CONR4R5, C3-6-heterocycloalkyl and formula (a, b, c): wherein R4-7 and A are as defined in the claims. Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of one or more kinases.